Loading clinical trials...
Loading clinical trials...
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study to Evaluate the Efficacy and Safety of Once-Daily, Intranasal Administration of GW685698X Aqueous Nasal Spray 50mcg and 100mcg for 2 Weeks in Pediatric Subjects Ages 2 to <12 Years With Seasonal Allergic Rhinitis (SAR)
The purpose of this study is to determine if the investigational drug is effective and safe in children with seasonal allergic rhinitis.
Age
2 - 12 years
Sex
ALL
Healthy Volunteers
No
GSK Investigational Site
Scottsdale, Arizona, United States
GSK Investigational Site
Little Rock, Arkansas, United States
GSK Investigational Site
Costa Mesa, California, United States
GSK Investigational Site
Cudahy, California, United States
GSK Investigational Site
Huntington Beach, California, United States
GSK Investigational Site
Long Beach, California, United States
GSK Investigational Site
Long Beach, California, United States
GSK Investigational Site
Mission Viejo, California, United States
GSK Investigational Site
Orange, California, United States
GSK Investigational Site
Riverside, California, United States
Start Date
March 1, 2005
Completion Date
November 1, 2005
Last Updated
September 15, 2016
576
Estimated participants
GW685698X
DRUG
Lead Sponsor
GlaxoSmithKline
NCT00779545
NCT00406783
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and ConditionsNCT00988247